Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
RGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$102.97 - $182.52
Previous CloseN/A
Volume111.19K
Average Volume (3M)934.21K
Market Cap
$6.95B
Enterprise Value$7.01B
Total Cash (Recent Filing)$697.23M
Total Debt (Recent Filing)$683.70M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 04, 2025EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding56,257,618
10 Day Avg. Volume712,859
30 Day Avg. Volume934,211
Financial Highlights & Ratios
PEG Ratio1.84
Price to Book (P/B)4.08
Price to Sales (P/S)12.69
P/FCF Ratio56.51
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue10.85
Enterprise Value/Gross Profit25.40
Enterprise Value/Ebitda58.91
Forecast
1Y Price Target
$177.17Price Target Upside48.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
EarningsRepligen's revenue of $182.4 million exceeded both the estimate of $177.1 million and the consensus of $175.2 million, highlighting strong financial performance.
Growth StrategyRepligen expects to double its revenues in the medium-term with minimal contribution from mergers and acquisitions, indicating a robust organic growth strategy.
Market PositionRepligen's differentiated product portfolio is yielding outsized growth in a normalizing bioprocessing market, with non-COVID organic growth up 17% and orders up over 20% year-over-year.
Bears Say
Earnings GuidanceRepligen expects full-year 2025 GAAP net earnings of $0.76 - $0.85 per diluted share, down from the original guidance range of $0.90 - $0.99 per diluted share.
Margin PressureMargins missed due to product mix dynamics, creating a 300-basis-point gross margin headwind.
Market SentimentA recent downturn in gene therapy sentiment due to recent news creates a 1% headwind in the newly raised FY25 guidance.
Repligen News
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $102.97 and its highest was $182.52 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is $6.95B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Nov 04, 2025 which is in 73 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Jul 29, 2025. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.388 by -$0.018.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.42.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,257,618 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.37 in its last earnings report, missing expectations of $0.388. Following the earnings report the stock price went up 4.722%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in RGEN
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$177.17 (48.07% Upside)
$177.17 (48.07% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 175.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $201.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.77%
12-Months-Change
Fundamentals
Return on Equity
-0.68%
Trailing 12-Months
Asset Growth
1.24%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corporation (RGEN) is a bioprocessing company that specializes in developing and manufacturing high-purity products for the biopharmaceutical industry. The company operates primarily in the life sciences sector, focusing on enabling the production of biologic drugs through its innovative technologies and products. Repligen's core offerings include chromatography resins, filtration systems, and various tools that enhance the efficiency and effectiveness of bioprocessing workflows. Its products are utilized in the production of monoclonal antibodies, therapeutic proteins, and vaccines, catering to a growing demand in the biopharmaceutical market.
RGEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant organic growth, record order growth, and improved financial guidance. However, challenges remain, particularly with the China market and gene therapy headwinds. Despite these challenges, the company is optimistic about its strategic investments and future growth opportunities.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$177.17
▲(48.07% Upside)
Technical Analysis
Ownership Overview
0.64% Insiders
35.60% Mutual Funds
28.79% Other Institutional Investors
13.77% Public Companies and
Individual Investors